Skip to content
Catalyst brief · Phase 3 readout · 26 days

IOLITE: KB803 in Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. · $KRYS · built 19 Nov 2026 from 16 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's small size of 16 patients may limit the strength of the evidence, but the focused patient population of Dystrophic Epidermolysis Bullosa and the clear main goal of evaluating safety and tolerability will help to provide a convincing result. F1 F2 F3

Base rates

  • The historical success rate of Phase 3 programmes in rare disease is 57.8%, which is an industry average and not a forecast for this trial. F12
  • KRYS has historically had an average absolute share move of 2.6% on past trial-result days, which is based on 2 past trial-result days on record. F13
  • It's important to note that averages, such as the 57.8% success rate and the 2.6% share move, are based on past data and do not predict the outcome of this trial. F12 F13

Filings

  • The company has a cash position of $912M and is not burning cash, with positive operating cash flow over the last 12 months. F14 F15
  • There have been no open-market insider purchases or unplanned sales reported in the last 90 days. F16
  • The primary completion date of the trial is estimated to be Dec 2026, which is 26 days from the current date. F9

The case for

  • The trial's focused patient population and clear main goal of evaluating safety and tolerability will help provide a convincing result, despite its small size of 16 patients. F1 F2 F3

The case against

  • The trial's small size of 16 patients may limit the strength of the evidence, which could lead to inconclusive results or a delay in reporting. F1 F2
  • The primary completion date is an estimate and is 26 days from the current date, leaving little time for any unforeseen delays or issues that could push the reporting date back. F9

Open questions

  • Can the small size of the trial be overcome by the quadruple blind and randomised design to provide convincing evidence?

8 AI sentences were removed by the fact check.

The facts

The trial

  • F1IOLITE is a Phase 3 trial of KB803 in Dystrophic Epidermolysis Bullosa, sponsored by Krystal Biotech, Inc. (KRYS). source ↗
  • F2The trial plans to enrol 16 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: To evaluate the safety and tolerability of KB803. source ↗
  • F4Blinding: quadruple blind. source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: 24 weeks. source ↗
  • F7Number of study arms: 2. source ↗

When

  • F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10That date is 9.0 months later than the date first registered for this trial (Mar 2026). source ↗
  • F11The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

Base rates

  • F12Historically 57.8% of Phase 3 programmes in rare disease (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F13KRYS has had 2 past trial-result days on record, with an average absolute share move of 2.6%. source ↗

Money, insiders and FDA

  • F14KRYS reported $912M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F15KRYS's operating cash flow was positive over the last 12 months, so it is not burning cash. source ↗
  • F16No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.